Infliximab treatment in ankylosing spondylitis: an observational study.
| Autor: | Nikas SN; Rheumatology Clinic, Department of Internal Medicine, University of Ioannina Medical School, 45110 Ioannina, Greece., Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of the rheumatic diseases [Ann Rheum Dis] 2005 Jun; Vol. 64 (6), pp. 940-2. Date of Electronic Publication: 2004 Nov 25. |
| DOI: | 10.1136/ard.2004.029900 |
| Abstrakt: | Objective: To investigate efficacy, toxicity, and drug discontinuation in patients with ankylosing spondylitis (AS) treated with infliximab. Methods: 35 patients with AS with mean (SD) age 42.5 (12.6) years and mean (SD) disease duration 14.5 (8.0) years were studied for 2 years. Patients entering the study had a negative tuberculin skin test, were fully informed about the treatment, and were followed up regularly. Infliximab, 5 mg/kg weight, was given intravenously at weeks 0, 2, 6, and every 8 weeks thereafter. Data concerning infliximab tolerability, adverse events, interval, and drug discontinuation were all recorded. Clinical improvement according to the BASDAI and the Ankylosing Spondylitis Assessment Study group (ASAS) 20%, 40%, and ASAS 5/6 response criteria were recorded. Results: After 1 year, 20 (57%) patients achieved the BASDAI 50% response criteria, 25 (71%) achieved ASAS 20%, 23 (66%) reached ASAS 40%, and 18 (51%) attained ASAS 5/6. After 2 years' treatment, 11 (31%) patients achieved BASDAI 50% response criteria, 14 (40%) ASAS 20%, 11 (31%) ASAS 40%, and 9 (26%) ASAS 5/6. Clinical improvement was associated with an improved BASFI and reduction of CRP. After 2 years' treatment, "infliximab survival" was 89%. Treatment was well tolerated and adverse events were mild; 3 patients discontinued the study. Conclusion: Infliximab was effective, safe, and well tolerated in patients with AS. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|